Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Viking Therapeutics

Novo Crashes After Obesity Drug Misses Lofty Expectations. Lilly, Viking And Amgen Surge.

Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly anticipated study.

Investors Business Daily

2 'Strong Buy' Biotech Stocks With 120% or More Upside Potential

2 'Strong Buy' Biotech Stocks With 120% or More Upside Potential

With the growing demand for cutting-edge therapies reshaping the healthcare landscape, here are two “Strong Buy”-rated biotech stocks with significant potential upside.

RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?

RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?

Robert F. Kennedy Jr.'s potential appointment to HHS has spooked Eli Lilly stock and stocks tied to popular weight-loss drugs.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral density loss.

Investors Business Daily

Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.

Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat

Viking Therapeutics reported strong weight loss for higher doses of its experimental obesity drug.

Investors Business Daily

Up 285% YTD, Is It Too Late to Buy This Biotech Stock?

Viking Therapeutics is making notable advancements in obesity treatment with VK2735 and exploring strategic partnerships for its NASH program, positioning itself at the forefront of metabolic and endocrine disorder therapies

inkl

Read news from The Economist, FT, and more,
with one subscription

Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review

Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review

The stock market was mixed for the week, but the Nasdaq hit a new high, fueled by Tesla, ServiceNow and more.

Investors Business Daily

Stock Market Today: Nasdaq Holds Gains As Tesla Soars; A New Buy Point Shows In ServiceNow (Live Coverage)

Stock Market Today: Nasdaq Holds Gains As Tesla Soars; A New Buy Point Shows In ServiceNow (Live Coverage)

The stock market today showed a mostly bullish streak in early trading Thursday amid a fall in weekly jobless claims and a torrent of earnings news.

Investors Business Daily

Viking Therapeutics Skyrockets After Dealing A Blow To Eli Lilly's Obesity Triplet

Viking Therapeutics Skyrockets After Dealing A Blow To Eli Lilly's Obesity Triplet

Viking Therapeutics stock ramped higher Thursday after the company outlined its weight-loss quad — a blow to Eli Lilly's experimental triple.

Investors Business Daily

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer

Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position.

Investors Business Daily

Snag This Biotech Stock Before November, Here's Why

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race

The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

Investors Business Daily

Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug

Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug

Eli Lilly will offer weight-loss drug Zepbound in a new form at roughly half the list price. Eli Lilly stock edged higher.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

3 'Strong-Buy'-Rated Russell 2000 Stocks With 54% to 110% Upside

Investing in these small caps could be rewarding in the long run.

Investors Business Daily

Viking Therapeutics Unveils Monthly Weight-Loss Shot, Rocking Eli Lilly, Novo Nordisk

Viking Therapeutics stock rocketed Thursday after the company said it's exploring a monthly dose of its weight-loss drug.

Investors Business Daily

Eli Lilly, Novo Nordisk — And Their Rivals — Skid On Roche's Weight-Loss Drug Results

Eli Lilly and Novo Nordisk fell Wednesday after Roche released positive early-stage trial data on its oral weight-loss drug.

Structure Therapeutics vs. Viking Therapeutics: Which Weight-Loss Drug Stock Wins?

With weight-loss drugs gaining traction, which biopharma stock wins?

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug

Viking Therapeutics stock falls despite seemingly positive test results for a drug that treats a serious liver disease.

5 Breakout Biotech Stocks Leading the Russell 2000 Higher

These small-cap biotech stocks are rallying hard in 2024, and still have room to keep leading the RUT higher.

Investors Business Daily

Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review

The Dow Jones and S&P 500 rose modestly on the stock market for the week, right around all-time high levels.

3 'Strong Buy' Growth Stocks to Scoop Up Now

High-growth stocks, such as cybersecurity name Zscaler, could be part of your equity portfolio in 2024 - if you're the type of investor who can successfully stomach massive drawdowns in share prices and valuations.

Investors Business Daily

Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss

Eli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are headliners in the expected boom in GLP-1 weight-loss drugs. But investors are making even more money on tangential players.

5 Russell 2000 Stocks Outperforming the 'Magnificent Seven' in 2024

The "Magnificent Seven" have lost some momentum in 2024, just as small-caps are starting to come on strong. Here's a closer look at five Russell 2000 stocks that are crushing the performance of their mega-cap peers so far this year.

Up 283% YTD, Is It Too Late to Buy Viking Therapeutics Stock?

Shares of Viking Therapeutics have been on an absolute tear in 2024, as the biotech stock gears up to enter the weight-loss drug market.

1 2

People

Robert F. Kennedy Jr

Todd Rosenbluth

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play